Reassuring short-term effect of corticosteroids for Kawasaki disease

Katrina Williams^{1

2}, Bronwyn Power¹, Georgina Tiller^{1

2}, William D Renton^{1

2}

Affiliations

¹ Department of Paediatric Rheumatology, Monash Children's Hospital, Melbourne, Victoria, Australia.
² Rheumatology Unit, Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.

Katrina Williams et al. J Paediatr Child Health. 2023 Jan.

. 2023 Jan;59(1):194-196.

doi: 10.1111/jpc.16301. Epub 2022 Dec 10.

Katrina Williams^{1

2}, Bronwyn Power¹, Georgina Tiller^{1

2}, William D Renton^{1

2}

¹ Department of Paediatric Rheumatology, Monash Children's Hospital, Melbourne, Victoria, Australia.
² Rheumatology Unit, Department of General Medicine, The Royal Children's Hospital, Melbourne, Victoria, Australia.

No abstract available

References

1. Kato H, Sugimura T, Akagi T et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379-85.
1. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J. Am. Coll. Cardiol. 1996; 28: 253-7.
1. Daniels LB, Gordon JB, Burns JC. Kawasaki disease: Late cardiovascular sequelae. Curr. Opin. Cardiol. 2012; 27: 572-7.
1. Oates-Whitehead RM, Baumer JH, Haines L et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 2003; 2003: CD004000.
1. Green J, Wardle AJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 2022; 5: CD011188.